HUM Stock Recent News
HUM LATEST HEADLINES
The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern.
Recently, Zacks.com users have been paying close attention to Humana (HUM). This makes it worthwhile to examine what the stock has in store.
Health insurer Humana Inc. NYSE: HUM reported its Q1 2024 earnings report to a less dramatic reaction than it got from its Q4 2023 report, causing shares to tumble more than 13%. Investors are still reeling over its vastly lowered EPS guidance stretching out to 2025.
The sell-off confirms that market players trade on future potential, not trailing results. The big insurer delivered an estimates-beating first quarter, but its profitability guidance left something to be desired.
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.
Humana (HUM) shares fell more than 5% in intraday trading Wednesday after it pulled its 2025 adjusted earnings guidance due to slower government healthcare spending.
Humana, Inc. (NYSE:HUM ) Q1 2024 Earnings Conference Call April 24, 2024 9:00 AM ET Company Participants Lisa Stoner - VP, IR Bruce Broussard - CEO & Director James Rechtin - President & COO Susan Diamond - CFO Conference Call Participants Ann Hynes - Mizuho Securities Kevin Fischbeck - Bank of America Merrill Lynch Gary Taylor - TD Cowen Scott Fidel - Stephens Benjamin Hendrix - RBC Capital Markets Nathan Rich - Goldman Sachs Group Stephen Baxter - Wells Fargo Securities Lisa Gill - JPMorgan Chase & Co. Andrew Mok - Barclays Joshua Raskin - Nephron Research Justin Lake - Wolfe Research Lance Wilkes - Sanford C. Bernstein & Co. A.J.
Humana (NYSE:HUM) shares fell after it pulled its 2025 profit guidance, reigniting investor concerns about the impact of rising medical costs on the insurer's bottom line. Humana (NYSE:HUM) in January downgraded its 2025 profit forecast from $37 per share to between $22 to $26 per share upon the expectation it would see a rise in medical claims as patients undergo non-urgent surgeries delayed due to the pandemic.
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.